Tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor (VEGF), which acts on the vascular endothelium, inhibitors of the mammalian target of rapamycin, which is involved in tumor growth, and recently, multi-tyrosine kinase inhibitors of AXL receptor tyrosine kinase (AXL) and MET receptor tyrosine kinase (MET), which are activated by the inhibition of the VEGF, have been approved and are currently being used for the treatment of unresectable/metastatic RCC [2,3]. The gene discussed is MET; the disease is renal cell adenocarcinoma.